
Juliette H Hughes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/552976/publications.pdf Version: 2024-02-01



#	Article	IF	Citations
1	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 762-772.	11.4	78
2	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 259-268.	3.6	21
3	Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 737-747.	3.6	18
4	Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria. Human Molecular Genetics, 2019, 28, 3928-3939.	2.9	16
5	Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism. Genes and Diseases, 2022, 9, 1129-1142.	3.4	13
6	Anatomical Distribution of Ochronotic Pigment in Alkaptonuric Mice is Associated with Calcified Cartilage Chondrocytes at Osteochondral Interfaces. Calcified Tissue International, 2021, 108, 207-218.	3.1	7
7	Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2â€dioxygenase deficiency in the liver is responsible for homogentisic acidâ€derived ochronotic pigmentation. JIMD Reports, 2021, 58, 52-60.	1.5	3
8	The contribution of mouse models in the rare disease alkaptonuria. Drug Discovery Today: Disease Models, 2020, 31, 37-43.	1.2	1